Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3248-3251

  Stepanova, Maria ^a,b   Younossi, Zobair M ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Direct acting antiviral agents; Health services accessibility; Hepatitis C; Interferon

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; AMERICAN; ARTICLE; CHRONIC HEPATITIS C; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG CONTRAINDICATION; FEMALE; HEALTH CARE DELIVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VIREMIA; HEALTH INSURANCE; HEPATITIS C, CHRONIC; INSURANCE; MEDICALLY UNINSURED; MIDDLE AGED; NUTRITION; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; ELIGIBILITY DETERMINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MEDICALLY UNINSURED; MIDDLE AGED; NUTRITION SURVEYS; PATIENT SELECTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84945477421     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3709-6     Document Type: Article

References (10)

1. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170–180.
2. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530–537.
3. Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318–1324.
4. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53:737–745.
5. The American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. Revised Aug 11, 2014. Accessed from http://www.hcvguidelines.org on August 24, 2014.
6. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
7. McKinsey Center for U.S. Health System Reform. Individual market: insights into consumer behavior at the end of open enrollment. Downloaded from http://healthcare.mckinsey.com/individual-market-insights-consumer-behavior-end-open-enrollment on September 2, 2014.
8. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat. 2013;20:550–555.
9. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The Cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015. doi:10.1093/cid/civ220.
10. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530–537.